Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

574 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early metabolic response in sequential FDG-PET/CT under cetuximab is a predictive marker for clinical response in first-line metastatic colorectal cancer patients: results of the phase II REMOTUX trial.
Berger AK, Lücke S, Abel U, Haag GM, Grüllich C, Stange A, Dietrich M, Apostolidis L, Freitag A, Trierweiler C, von Gall C, Ose J, Giesel F, Weber TF, Lordick F, Haberkorn U, Jäger D. Berger AK, et al. Among authors: jager d. Br J Cancer. 2018 Jul;119(2):170-175. doi: 10.1038/s41416-018-0152-4. Epub 2018 Jul 2. Br J Cancer. 2018. PMID: 29961759 Free PMC article. Clinical Trial.
Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy.
Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, Heger U, Apostolidis L, Berger AK, Springfeld C, Lasitschka F, Jäger D, von Knebel Doeberitz M, Kloor M. Haag GM, et al. Among authors: jager d. Int J Cancer. 2019 Apr 1;144(7):1697-1703. doi: 10.1002/ijc.32030. Epub 2019 Jan 4. Int J Cancer. 2019. PMID: 30499151
Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression.
Apostolidis L, Pfeiffenberger J, Gotthardt D, Radeleff B, Mehrabi A, Schemmer P, Jäger D, Schirmacher P, Stremmel W, Schulze-Bergkamen H, Springfeld C, Weiss KH. Apostolidis L, et al. Among authors: jager d. Gastrointest Tumors. 2018 Sep;5(1-2):38-46. doi: 10.1159/000487635. Epub 2018 Apr 11. Gastrointest Tumors. 2018. PMID: 30574480 Free PMC article.
Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate.
Apostolidis L, Nientiedt C, Winkler EC, Berger AK, Kratochwil C, Kaiser A, Becker AS, Jäger D, Hohenfellner M, Hüttenbrink C, Pahernik S, Distler FA, Grüllich C. Apostolidis L, et al. Among authors: jager d. Oncotarget. 2019 Jan 1;10(1):17-29. doi: 10.18632/oncotarget.26523. eCollection 2019 Jan 1. Oncotarget. 2019. PMID: 30713600 Free PMC article.
574 results